XXII (XXII) Stock Analysis
Verdict: AVOID
Catastrophic cash burn and negative gross margins make extreme dilution or bankruptcy imminent, rendering XXII non-investable.
Investment score: 9/100
Is XXII Stock Worth Reviewing? AI Model Thesis
The AI model assigns an AVOID rating on 22nd Century Group Inc due to negative gross margins, rapid cash depletion, and severe multi-year dilution.
Should You Buy or Sell XXII Stock? Model Reasoning
The AI model identifies structural financial distress: XXII generates negative gross margins (-19.44%), severe operational loss (-85.04%), and faces a cash burn of -$7.72M against $7.15M in cash reserves. Without capital injections, insolvency or massive equity dilution remains highly probable within 11 months.
XXII Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Annual operating cash burn of ~$7.72M continues without immediate operational break-even","Gross margins remain negative (-19.4% in 2025) due to fixed production costs and low volume","Share count continues to dilute existing equity holders to cover liquidity shortfalls"]
XXII Risk & Opportunity Analysis
Key Investment Risks
- Severe Cash Burn and Imminent Liquidity Shortfall — Operational cash flow of -$7.72M against $7.15M in cash leaves approximately 11 months of runway before requiring additional equity offerings.
- Negative Gross Margins and Declining Top-Line Sales — Revenue fell 27.44% to $7.05M in 2025 while gross margin remained negative at -19.44%, forcing losses on every product unit sold.
- Persistent Share Dilution and Capital Structure Instability — Frequent reverse splits and share issuances continue to wipe out existing shareholder equity value.
- Extreme Technical Breakdown and Liquidity Risk — A 35.47% single-day drop to 1.51 USD and a 99.8% decline from 52-week highs highlight extreme illiquidity and technical breakdown.
Growth Opportunities & Upside Drivers
- Potential Licensing or IP Monetization of Low-Nicotine Gene Tech — Monetizing proprietary plant-breeding patents could generate non-dilutive cash prior to mid-2027.
- FDA Regulatory Mandates on Maximum Nicotine Content — Federal rules mandating reduced nicotine in commercial cigarettes would significantly boost VLN brand adoption.
- Cost-Reduction and Operational Restructuring — Cutting operating expenses below $5M per year could extend the current cash runway past 18 months.
- Hemp and Cannabinoid Commercial Partnerships — Successful joint ventures with partners like Keygene N.V. could unlock non-tobacco revenue growth opportunities.
XXII Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About XXII (XXII)
Is XXII stock a good investment?
The cached TradeMates AI model rates XXII as AVOID with an investment score of 9/100. The AI model assigns an AVOID rating on 22nd Century Group Inc due to negative gross margins, rapid cash depletion, and severe multi-year dilution. This is algorithmic model output, not personal investment advice.
Does XXII pay a dividend?
The cached stock data on this page does not show a positive dividend yield for XXII. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does XXII stock do?
Agricultural biotechnology company developing ultra-low nicotine (VLN) tobacco products and proprietary hemp/cannabis plant varieties for research, commercial, and life science applications.
What is XXII stock's price target?
This cached page does not contain a precise model fair value for XXII.
Is XXII stock a buy?
The TradeMates model verdict for XXII is AVOID with an investment score of 9/100. Treat this as a model signal to review, not a personal buy recommendation.
Is XXII a good dividend stock?
XXII is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.